News

NASH and all its complications are especially prevalent in patients with severe obesity and type 2 diabetes. Yet few study data exist on biomarker performance within this patient group, in order to move away from the necessity of liver biopsy in clinical practice.

Sami Qadri, MD & Hannele Yki-Järvinen, MD et al. performed a study to evaluate the use of the M30 Apoptosense ELISA® to diagnose NASH or fibrotic NASH in an obese cohort.

They found that plasma levels of M30® associated with the full histological spectrum of NASH and also had a good ability to identify both NASH and fibrotic NASH with high sensitivity and specificity!

Click here to access the full White Paper!

🚌 We’re aboard the bus to London for a face-to-face ILC2022 with EASL | The Home of Hepatology! We are happy to yet again be an industry partner for the biggest liver event in Europe!

The latest in hepatology is happening 📅 22–26 June.
🤝 Join us at the highlight of the year! Register today, and lets meet and discuss liver biomarkers at our booth.

• M30 Apoptosense® ELISA in detecting NAFLD

• – What is NAFLD and what is the role of K18 in NAFLD?
• – How can the M30® aid in staging NAFLD and detecting NASH?
• – How can M30® incorporating biomarker scores help in detecting fibrotic NASH?

Click here to access the full brochure!

• Keratin 18 in NAFLD clinical trials

• – What is NAFLD and what is the role of K18 in NAFLD?
• – What are the main challenges in todays NAFLD clinical trials?
• – How can the VLVbio K18 assays aid in pre-screening subjects
  for inclusion in the trials?
• – How can the VLVbio K18 assays be used as an end-point in the trials?

Click here to access the full broschure!

• M30 Apoptosense® ELISA in paediatric NAFLD

• – What is paediatric NAFLD and what is the role of K18 in NAFLD?
• – How can M30® aid in detecting NASH in children?
• – How can M30® be incorporated into screening of patients with
  childhood obesity to identify metabolic complications?

Click here to access the full broschure!